{"id":"hylenex","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":["hyaluronidase human injection","Hylenex (R) recombinant","Hyaluronidase"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-04-17","unitCost":"$53.3399/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$19,202","description":"HYLENEX 150 UNITS/ML VIAL","retrievedDate":"2026-04-07"}],"offLabel":[],"timeline":[],"_dailymed":{"setId":"3023cc56-ed4b-4e87-b3a1-81b20943f658","title":"HYLENEX RECOMBINANT (HYALURONIDASE) INJECTION, SOLUTION [ANTARES PHARMA, INC.]"},"ecosystem":[],"_scrapedAt":"2026-03-27T23:41:12.702Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03306615","phase":"PHASE2","title":"Peripheral Modulation of Muscle Stiffness and Spasticity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2021-10-11","conditions":"Muscle Spasticity","enrollment":56},{"nctId":"NCT05293249","phase":"PHASE1","title":"dMAbs for Prevention of COVID-19","status":"COMPLETED","sponsor":"Pablo Tebas","startDate":"2022-05-19","conditions":"Healthy Volunteers","enrollment":61},{"nctId":"NCT02199028","phase":"PHASE1","title":"Hyaluronidase Effect on Infusion Set Life","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-07","conditions":"Type 1 Diabetes Mellitus","enrollment":30},{"nctId":"NCT02265575","phase":"PHASE2","title":"Hylenex-Assisted Resuscitation in Kenya (HARK) Trial for the Management of Dehydration","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-10","conditions":"Dehydration","enrollment":51},{"nctId":"NCT01526733","phase":"PHASE4","title":"Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2011-12","conditions":"Type 1 Diabetes Mellitus","enrollment":25},{"nctId":"NCT00705536","phase":"PHASE1","title":"Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2007-12","conditions":"Diabetes Mellitus","enrollment":26},{"nctId":"NCT01194245","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 1","enrollment":135},{"nctId":"NCT00774800","phase":"PHASE2","title":"Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2008-10","conditions":"Type 1 Diabetes Mellitus","enrollment":22},{"nctId":"NCT03662334","phase":"PHASE4","title":"A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2013-10-03","conditions":"Type 1 Diabetes Mellitus","enrollment":14},{"nctId":"NCT01987609","phase":"PHASE2","title":"Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques","status":"COMPLETED","sponsor":"Tissa Hata, MD","startDate":"2015-07","conditions":"Psoriasis","enrollment":7},{"nctId":"NCT01848990","phase":"PHASE4","title":"CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2013-03","conditions":"Type 1 Diabetes Mellitus","enrollment":456},{"nctId":"NCT00773175","phase":"PHASE4","title":"Subcutaneous Rehydration Compared to Intravenous Rehydration","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2008-10","conditions":"Dehydration","enrollment":148},{"nctId":"NCT00656370","phase":"PHASE4","title":"Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2007-12","conditions":"Healthy","enrollment":15},{"nctId":"NCT00803972","phase":"PHASE1","title":"Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2008-11","conditions":"Healthy Volunteers","enrollment":42},{"nctId":"NCT01139294","phase":"PHASE4","title":"Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2010-02","conditions":"Dehydration, Cardiac Output, Pediatrics","enrollment":17},{"nctId":"NCT02654522","phase":"PHASE1","title":"The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers","status":"COMPLETED","sponsor":"Steve Yoelin M.D. Medical Associates, Inc.","startDate":"2016-01","conditions":"Dermal Filler","enrollment":15},{"nctId":"NCT01120431","phase":"PHASE4","title":"Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)","status":"WITHDRAWN","sponsor":"Baxter Healthcare Corporation","startDate":"2010-05","conditions":"Dehydration","enrollment":""},{"nctId":"NCT00883558","phase":"PHASE2","title":"Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT01194258","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type II","enrollment":132},{"nctId":"NCT00916357","phase":"PHASE2","title":"Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":23},{"nctId":"NCT01275131","phase":"PHASE1","title":"Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2011-01","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT00862849","phase":"PHASE1","title":"Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2009-03","conditions":"Diabetes Mellitus","enrollment":22},{"nctId":"NCT00979875","phase":"PHASE1","title":"A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2009-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT00547664","phase":"NA","title":"Efficacy of Hylenex in the Treatment of Pain Among Hospice Patients","status":"COMPLETED","sponsor":"HPC Healthcare, Inc.","startDate":"2008-01","conditions":"Pain Management","enrollment":88},{"nctId":"NCT01572012","phase":"PHASE1","title":"Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2012-02","conditions":"Healthy","enrollment":12},{"nctId":"NCT00493220","phase":"PHASE1","title":"Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2007-06","conditions":"Healthy","enrollment":30},{"nctId":"NCT00477152","phase":"PHASE4","title":"Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2007-08","conditions":"Dehydration","enrollment":52},{"nctId":"NCT00807885","phase":"PHASE4","title":"Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2008-12","conditions":"Dehydration","enrollment":100},{"nctId":"NCT01116102","phase":"PHASE4","title":"Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)","status":"TERMINATED","sponsor":"Baxter Healthcare Corporation","startDate":"2010-05","conditions":"Dehydration","enrollment":20},{"nctId":"NCT00435604","phase":"PHASE1","title":"A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2007-02","conditions":"Healthy","enrollment":15},{"nctId":"NCT00740727","phase":"PHASE1","title":"EASI Access II --- Follow-up Study to the EASI Access Trial","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-02","conditions":"Disaster Medicine, Difficult Intravenous Access, Dehydration","enrollment":18},{"nctId":"NCT00593281","phase":"PHASE3","title":"INFUSE Morphine Study","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2006-01","conditions":"Pain","enrollment":13},{"nctId":"NCT00311519","phase":"PHASE4","title":"A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2005-11","conditions":"Healthy","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":39,"reaction":"HYPERSENSITIVITY"},{"count":35,"reaction":"OFF LABEL USE"},{"count":30,"reaction":"DRUG INEFFECTIVE"},{"count":13,"reaction":"SWELLING"},{"count":10,"reaction":"BURNING SENSATION"},{"count":7,"reaction":"DRY EYE"},{"count":7,"reaction":"PAIN"},{"count":7,"reaction":"SWELLING FACE"},{"count":6,"reaction":"ARTHRALGIA"},{"count":6,"reaction":"ERYTHEMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[{"date":"20120301","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20051202","type":"ORIG","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20141016","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20160621","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20240112","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20160121","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20081001","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20120320","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20150417","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20130723","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20160728","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20091211","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20150727","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20060609","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"},{"date":"20140506","type":"SUPPL","sponsor":"HALOZYME THERAP","applicationNumber":"BLA021859"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":7,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Hylenex","genericName":"Hylenex","companyName":"Vanderbilt University Medical Center","companyId":"vanderbilt-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}